# A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

> **NCT06528301** · PHASE1 · RECRUITING · sponsor: **Umoja Biopharma** · enrollment: 106 (estimated)

## Conditions studied

- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin (NHL)
- Lymphoma, Large B-Cell, Diffuse (DLBCL)
- Chronic Lymphocytic Leukemia (CLL)

## Interventions

- **GENETIC:** UB-VV111
- **DRUG:** rapamycin

## Key facts

- **NCT ID:** NCT06528301
- **Lead sponsor:** Umoja Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06528301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06528301, "A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06528301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*